Company intelligence / Profile preview
KeifeRx
McLean, Virginia, United States
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 3
01
Overview
Lead candidate KFRX01 (Nilotinib) is close to entering Phase 2b trials for early Alzheimer's disease; KFRX02 (Bosutinib) is ready to enter Phase 2b trials for Lewy body dementia. The company's approach focuses on repurposing cancer drugs (TKIs) to induce autophagy and eliminate toxic proteins implicated in neurodegenerative diseases.
- Therapeutic areas
- ImmunologyNeurologyInfectious Diseases
- Modalities
- Small moleculesTyrosine kinase inhibitors (TKIs)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Georgetown University
Beyond the preview
Go deeper on KeifeRx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KeifeRx.